Clinical Effect and Oxylipidomics Study of Transcutaneous Electrical Acupoint Stimulation Combined with Conventional Western Medicine on Chronic Coronary Syndrome

Transcutaneous Electrical Acupoint Stimulation of ST36/PC6 for the treatment of chronic coronary syndrome: a multicenter randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400079383

Enrollment

Unknown

Registered

2024-01-02

Start date

2024-01-31

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Coronary Syndrome

Interventions

transcutaneous electrical acupoint stimulation Combined with Conventional Western Medicine:transcutaneous electrical acupoint stimulation Combined with Conventional Western Medicine

Sham-transcutaneous electrical acupoint stimulation Combined with Conventional Western Medicine:Sham-transcutaneous electrical acupoint stimulation Combined with Conventional Western Medicine

Conventional Western Medicine: Conventional Western Medicine

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Comply with the diagnostic criteria of the 2019 ESC "Diagnosis and Guidelines for Chronic Coronary Syndrome"; (2) Stable angina pectoris; (3) The classification criteria for angina pectoris are based on the severity classification of angina pectoris by the Canadian Cardiovascular Society, which is divided into levels I, II, and III; (4) Age range from 30 to 80 years old, regardless of gender; (5) Angina pectoris = 3 months, with = 2 episodes per week; (6) Sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Poor control of blood pressure and blood sugar; (2) Severe cardiovascular diseases such as severe cardiopulmonary insufficiency, severe arrhythmia, severe arterial stenosis, dissection, etc; (3) Patients with severe cerebrovascular diseases, severe liver diseases, kidney or blood system diseases, or malignant tumors; (4) Individuals with bleeding tendencies or allergic constitution; (5) Patients with pacemakers installed; (6) Pregnant or lactating women, or those with fertility requirements in the past six months; (7) Those who have merged mental illnesses or are unwilling to cooperate; (8) Individuals who have participated or are currently participating in other clinical trials within the past 3 months.

Design outcomes

Primary

Measure	Time frame
6-minute walk test;	—

Secondary

Measure	Time frame
electrocardiogram; dynamic electrocardiogram.;Frequency of angina attacks;Seattle Angina Scale Score;VAS score for angina pain;Usage of Nitroglycerin or Suxiaojiuxin Pills;hs-CRP;serum lipids;Heart rate variability;	—

Countries

China

Contacts

Public ContactHongfeng Wang

The Third Affiliated Hospital of Changchun University of Chinese Medicine

mengering123@163.com+86 431 8671 4973

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026